Association between Adverse Reactions to the First and Second Doses of COVID-19 Vaccine
Open Access
Abstract
This study investigated the frequency of adverse reactions to COVID-19 vaccines in Japan and the impact of first-dose adverse reactions on second-dose adverse reactions. Individuals who received an mRNA COVID-19 vaccine at our center in March or April 2021 were included. Data were collected using questionnaires. The main factors were age (60 years), sex, underlying disease, and first-dose adverse reaction. The primary outcomes were incidence of local and systemic adverse reactions (ARs) attributable to the vaccine. Logistic regression was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs). Among 671 participants, 90% experienced local or systemic ARs. An AR to the first dose was associated with a significantly increased risk of an AR to the second dose (OR: 49.63, 95% CI: 21.96–112.16). ARs were less common among men than among women (OR: 0.36, 95% CI: 0.17–0.76). Local ARs were less common among those aged 60 years or older (OR: 0.35, 95% CI: 0.18–0.66), whereas systemic ARs were more common among those aged under 40 years. Information on ARs to the first dose is important for healthcare providers and recipients when making vaccination decisions.Keywords
This publication has 19 references indexed in Scilit:
- Review of COVID-19 mRNA Vaccines: BNT162b2 and mRNA-1273Journal of Pharmacy Practice, 2021
- Minor to Moderate Side Effects of Pfizer-BioNTech COVID-19 Vaccine Among Saudi Residents: A Retrospective Cross-Sectional StudyInternational Journal of General Medicine, 2021
- Prevalence of COVID-19 Vaccine Side Effects among Healthcare Workers in the Czech RepublicJournal of Clinical Medicine, 2021
- Allergische Reaktionen auf COVID-19-Impfstoffe – Evidenz und praxisorientiertes VorgehenDie Innere Medizin, 2021
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineNew England Journal of Medicine, 2020
- Implications of Sex Differences in Immunity for SARS-CoV-2 Pathogenesis and Design of Therapeutic InterventionsImmunity, 2020
- Cost-effectiveness of adult vaccinations: A systematic reviewVaccine, 2019
- Vaccine hesitancy: Definition, scope and determinantsVaccine, 2015
- Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trialVaccine, 2015
- The Xs and Y of immune responses to viral vaccinesThe Lancet Infectious Diseases, 2010